Copyright
©The Author(s) 2023.
World J Cardiol. Apr 26, 2023; 15(4): 154-164
Published online Apr 26, 2023. doi: 10.4330/wjc.v15.i4.154
Published online Apr 26, 2023. doi: 10.4330/wjc.v15.i4.154
Table 1 Patients’ characteristics
| Group O | Group Y | P value | ||
| No. (%) | 77 (82) | 17 (18) | ||
| Age (yr) | 72 ± 7 | 54 ± 5 | < 0.01 | |
| Body mass index | 23.7 ± 4.5 | 24.5 ± 5.3 | 0.50 | |
| Coronary risk factors (%) | ||||
| Smoking (active/former/never) | 3/5/69 | 3/4/10 | < 0.01 | |
| Hypertension | 58 (75) | 7 (41) | < 0.01 | |
| Dyslipidemia | 55 (77) | 10 (59) | 0.31 | |
| Diabetes mellitus | 12 (16) | 2 (12) | 0.68 | |
| Alcohol consumer (%) | 10 (13) | 5 (29) | 0.09 | |
| Family history of CAD (%) | 18 (23) | 5 (29) | 0.60 | |
| MtS (%) | 13 (17) | 4 (24) | 0.52 | |
| CKD (%) | 27 (35) | 1 (6) | 0.02 | |
Table 2 Blood chemical parameters in the two groups
| Group O | Group Y | P value | |
| Total cholesterol (mg/dL) | 202 ± 33 | 196 ± 37 | 0.53 |
| Triglyceride (mg/dL) | 131 ± 73 | 119 ± 46 | 0.54 |
| HDL-cholesterol (mg/dL) | 63 ± 17 | 62 ± 18 | 0.82 |
| LDL-cholesterol (md/dL) | 113 ± 29 | 111 ± 32 | 0.82 |
| Fasting blood sugar (md/dL) | 100 ± 16 | 101 ± 17 | 0.93 |
| Hemoglobin A1C (%) | 6.0 ± 0.7 | 5.7 ± 0.6 | 0.10 |
| C-reactive protein (mg/dL) | 0.05 (0.02, 0.13) | 0.07 (0.02, 0.15) | 0.81 |
| eGFR (mL/min/1.73 m2) | 68.8 ± 16.8 | 77.5 ± 13.2 | 0.05 |
| BNP (pg/mL) | 22 (14, 54) | 15 (10, 29) | 0.09 |
Table 3 Echographic parameters in the two groups
| Group O | Group Y | P value | |||
| UCG | |||||
| LVEF (%) | 68 ± 9 | 66 ± 6 | 0.46 | ||
| Brachial ultrasonography | |||||
| All studied patients | |||||
| No. | 77 | 17 | |||
| Heart rate (/min) | 66 ± 10 | 67 ± 13 | 0.85 | ||
| Mean blood pressure | 100 ± 14 | 94 ± 14 | 0.16 | ||
| Brachial blood flow | |||||
| Baseline (mL/min) | 61 ± 44 | 59 ± 52 | 0.87 | ||
| % increase | 384 ± 490 | 327 ± 265 | 0.59 | ||
| Brachial artery diameter (mm) | |||||
| Baseline | 3.5 ± 0.5 | 3.5 ± 0.5 | 0.83 | ||
| Hyperemia | 3.7 ± 0.5 | 3.6 ± 0.5 | 0.88 | ||
| After NTG | 4.0 ± 0.5 | 4.2 ± 0.4 | 0.25 | ||
| FMD (%) | 4.3 ± 3.2 | 4.5 ± 3.3 | 0.75 | ||
| NID (%) | 13.6 ± 5.4 | 20.5 ± 8.6 | < 0.01 | ||
| Patients who did not take any coronary vasodilators | |||||
| No. | 39 | 14 | |||
| Brachial artery diameter (mm) | |||||
| Baseline | 3.5 ± 0.5 | 3.6 ± 0.4 | 0.68 | ||
| Hyperemia | 3.6 ± 0.6 | 3.7 ± 0.4 | 0.60 | ||
| After NTG | 4.0 ± 0.5 | 4.2 ± 0.4 | 0.21 | ||
| FMD (%) | 4.1 ± 3.1 | 4.3 ± 3.5 | 0.82 | ||
| NID (%) | 14.6 ± 5.7 | 18.5 ± 6.5 | 0.04 | ||
Table 4 Vasospastic angina-related parameters in the two groups
| Group O | Group Y | P value | |||
| Chest symptoms | |||||
| Rest/Exercise/Both | 60/9/9 | 14/1/2 | 0.78 | ||
| Maximum duration of attack (min) | 20 ± 27 | 16 ± 28 | 0.10 | ||
| Diseased duration (M) | 5 (1, 48) | 12 (3, 42) | 0.78 | ||
| No. of anginal attacks (/M) | |||||
| At admission | 4 (1, 10) | 4 (1, 10) | 0.43 | ||
| At follow-up | 0 (0, 1) | 2 (0.1, 2.8) | < 0.01 | ||
| No. | 69 | 16 | |||
| Medications | |||||
| Taking statins at admission (%) | 36 (47) | 7 (46) | 0.68 | ||
| Taking antiplatelet drugs at admission (%) | 20 (26) | 1 (6) | 0.07 | ||
| Taking vasodilators at admission (%) | 38 (49) | 3 (18) | 0.02 | ||
| No. coronary vasodilators | |||||
| At admission | 0 (0,1) | 0 (0, 0) | 0.01 | ||
| 0.6 ± 0.7 | 0.2 ± 0.4 | 0.01 | |||
| At discharge | 1 (1, 1) | 1 (1, 1) | 0.01 | ||
| 1.2 ± 0.5 | 0.9 ± 0.3 | 0.02 | |||
| At follow-up | 1 (1, 2) | 1.5 (1, 2) | 0.52 | ||
| 1.5 ± 0.9 | 1.6 ± 0.9 | 0.53 | |||
Table 5 Coronary angiography spasm provocation test parameters in the two groups
| Group O | Group Y | P value | ||
| CAG | ||||
| Atherosclerotic change (%) | 47 (61) | 0 (0) | < 0.01 | |
| Myocardial bridging (%) | 13 (17) | 3 (18) | 0.94 | |
| SPT | ||||
| Focal/diffuse/focal and diffuse | 16/48/33 | 0/15/2 | 0.08 | |
| Presence of focal spasm (%) | 29 (38) | 2 (12) | 0.04 | |
| Multi-vessels spasm (%, No.) | 39 (57, 68) | 8 (67, 12) | 0.56 | |
| Vessels of spasm | ||||
| RCA (%, No.) | 44 (62, 71) | 10 (67, 15) | 0.72 | |
| LAD (%, No.) | 70 (96, 73) | 13 (93, 14) | 0.62 | |
| LCX (%, No.) | 5 (7, 72) | 5 (38, 13) | < 0.01 | |
| An unavoidable use of NTG (%) | 14 (18) | 8 (47) | 0.01 | |
| ST deviation during SPT (%) | 10 (13) | 5 (29) | 0.09 | |
- Citation: Teragawa H, Oshita C, Uchimura Y. Vasospastic angina in women: Clinical backgrounds and prognoses of patients younger than and older than 60 years. World J Cardiol 2023; 15(4): 154-164
- URL: https://www.wjgnet.com/1949-8462/full/v15/i4/154.htm
- DOI: https://dx.doi.org/10.4330/wjc.v15.i4.154
